

Michael L Steinberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4450951/publications.pdf>

Version: 2024-02-01

149
papers

3,656
citations

201674

27
h-index

168389

53
g-index

150
all docs

150
docs citations

150
times ranked

4530
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 803-811.	10.7	261
2	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	7.4	252
3	⁶⁸ Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 230-237.	5.0	226
4	Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2019, 2, e188006.	5.9	221
5	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	1.9	140
6	Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. <i>Cancer</i> , 2016, 122, 447-455.	4.1	123
7	Choosing Wisely: The American Society for Radiation Oncology's Top 5 list. <i>Practical Radiation Oncology</i> , 2014, 4, 349-355.	2.1	102
8	High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 667-674.	0.8	101
9	Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017, 71, 766-773.	1.9	83
10	Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721.	5.0	81
11	Online Adaptive Radiation Therapy: Implementation of a New Process of Care. <i>Cureus</i> , 2017, 9, e1618.	0.5	77
12	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 304-316.	10.7	68
13	A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 1829-1836.	7.0	63
14	4D Noncoplanar Stereotactic Body Radiation Therapy for Head-and-Neck Cancer: Potential to Improve Tumor Control and Late Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 401-409.	0.8	62
15	Value: A Framework for Radiation Oncology. <i>Journal of Clinical Oncology</i> , 2014, 32, 2864-2870.	1.6	47
16	Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer. <i>British Journal of Radiology</i> , 2017, 90, 20160739.	2.2	43
17	Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 319-325.	0.6	43
18	Feasibility of prostate robotic radiation therapy on conventional C-arm linacs. <i>Practical Radiation Oncology</i> , 2014, 4, 254-260.	2.1	38

#	ARTICLE	IF	CITATIONS
19	Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs. <i>Physics in Medicine and Biology</i> , 2020, 65, 175006.	3.0	38
20	Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 455-461.	0.6	37
21	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	1.9	37
22	Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1154-1161.	1.3	35
23	A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic body radiotherapy for central early-stage non-small cell lung cancer. <i>Medical Dosimetry</i> , 2016, 41, 87-91.	0.9	31
24	Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 44-52.	0.8	31
25	Clinical Outcomes Using Magnetic Resonance-Guided Stereotactic Body Radiation Therapy in Patients With Locally Advanced Cholangiocarcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 189-195.	1.2	31
26	The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. <i>Cancer</i> , 2018, 124, 1673-1681.	4.1	30
27	The International Cancer Expert Corps: A Unique Approach for Sustainable Cancer Care in Low and Lower-Middle Income Countries. <i>Frontiers in Oncology</i> , 2014, 4, 333.	2.8	29
28	Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 539.	2.8	29
29	Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. <i>BMC Cancer</i> , 2021, 21, 538.	2.6	29
30	Feasibility of magnetic resonance imaging-guided liver stereotactic body radiation therapy: A comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based intensity modulated radiation therapy. <i>Practical Radiation Oncology</i> , 2015, 5, 330-337.	2.1	28
31	Magnetic resonance imaging guided reirradiation of recurrent and second primary head and neck cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 167-175.	1.2	28
32	Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial. <i>Radiotherapy and Oncology</i> , 2022, 170, 14-20.	0.6	28
33	SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 268-275.	2.1	27
34	Treatment trends for patients with brain metastases: Does practice reflect the data?. <i>Cancer</i> , 2017, 123, 2274-2282.	4.1	27
35	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. <i>JAMA Oncology</i> , 2019, 5, 91.	7.1	27
36	Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 731-737.	0.8	27

#	ARTICLE	IF	CITATIONS
37	Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, Executive Summary. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 11-17.	0.8	26
38	Evaluation of Sex Distribution of Industry Payments Among Radiation Oncologists. <i>JAMA Network Open</i> , 2019, 2, e187377.	5.9	26
39	Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer. <i>Practical Radiation Oncology</i> , 2015, 5, 257-262.	2.1	24
40	Time-Driven Activity-Based Costing Comparison of CT-Guided Versus MR-Guided SBRT. <i>JCO Oncology Practice</i> , 2020, 16, e1378-e1385.	2.9	24
41	Dose response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. <i>Radiotherapy and Oncology</i> , 2021, 154, 207-213.	0.6	24
42	Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 255-255.	1.6	24
43	The patient's perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2015, 90, 230-233.	2.0	22
44	Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 516-525.	0.8	22
45	Location Matters: Stage I Non-Small-Cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes. <i>Clinical Lung Cancer</i> , 2017, 18, e137-e142.	2.6	21
46	Patient-reported quality of life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. <i>Cancer</i> , 2018, 124, 521-529.	4.1	21
47	Assessment of Differences in Clinical Activity and Medicare Payments Among Female and Male Radiation Oncologists. <i>JAMA Network Open</i> , 2019, 2, e190932.	5.9	21
48	Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 628-636.	0.8	20
49	Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis. <i>Cancer Medicine</i> , 2021, 10, 5897-5906.	2.8	20
50	Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 203-210.	0.6	20
51	Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. <i>Brachytherapy</i> , 2017, 16, 1106-1112.	0.5	19
52	Respiratory motion-resolved, self-gated 4D-MRI using Rotating Cartesian K-space (ROCK): Initial clinical experience on an MRI-guided radiotherapy system. <i>Radiotherapy and Oncology</i> , 2018, 127, 467-473.	0.6	19
53	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020, 151, 26-32.	0.6	19
54	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient data Network Meta-analysis from the MARCAP Consortium. <i>European Urology</i> , 2022, 82, 106-114.	1.9	19

#	ARTICLE	IF	CITATIONS
55	High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2017, 16, 299-305.	0.5	18
56	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	1.9	18
57	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	7.1	18
58	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	5.9	18
59	Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 832-839.	0.8	17
60	The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy. <i>British Journal of Radiology</i> , 2016, 89, 20150963.	2.2	17
61	Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. <i>Cureus</i> , 2018, 10, e2324.	0.5	17
62	Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1319-1325.	1.1	16
63	Gaps in Radiation Therapy Awareness: Results From an Educational Multi-institutional Survey of US Internal Medicine Residents. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1153-1161.	0.8	16
64	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	5.9	16
65	Clinical Indicators of Psychosocial Distress Predict for Acute Radiation-Induced Fatigue in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer: An Analysis of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 946-955.	0.8	13
66	The Declining Residency Applicant Pool: A Multi-Institutional Medical Student Survey to Identify Precipitating Factors. <i>Advances in Radiation Oncology</i> , 2021, 6, 100597.	1.2	13
67	Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 133-138.	0.6	12
68	External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1045-1052.	0.8	12
69	Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma. <i>Gynecologic Oncology</i> , 2017, 144, 21-27.	1.4	12
70	A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 564-573.	0.8	12
71	Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. <i>Urology</i> , 2019, 126, 89-95.	1.0	12
72	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 930-935.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	5.9	12
74	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	1.9	12
75	Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma. <i>Practical Radiation Oncology</i> , 2015, 5, 366-373.	2.1	11
76	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.8	11
77	The Timeliness Initiative: Continuous Process Improvement for Prompt Initiation of Radiation Therapy Treatment. <i>Advances in Radiation Oncology</i> , 2020, 5, 1014-1021.	1.2	11
78	The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 135-139.	3.9	11
79	Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation. <i>Medical Physics</i> , 2021, 48, 3262-3372.	3.0	11
80	Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial. <i>Cancers</i> , 2021, 13, 2802.	3.7	11
81	Evaluation of T2-Weighted MRI for Visualization and Sparing of Urethra with MR-Guided Radiation Therapy (MRgRT) On-Board MRI. <i>Cancers</i> , 2021, 13, 3564.	3.7	11
82	Accelerated 3D bSSFP imaging for treatment planning on an MRI-guided radiotherapy system. <i>Medical Physics</i> , 2018, 45, 2595-2602.	3.0	10
83	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.8	10
84	Simultaneous radiosurgery for multiple brain metastases: technical overview of the UCLA experience. <i>Radiation Oncology</i> , 2021, 16, 221.	2.7	10
85	Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 149-154.	0.8	9
86	Cost Effectiveness of External Beam Radiation Therapy versus Percutaneous Image-Guided Cryoablation for Palliation of Uncomplicated Bone Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1221-1232.	0.5	9
87	Time-Driven Activity-Based Costing Analysis of Telemedicine Services in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 430-434.	0.8	9
88	Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning. <i>Radiotherapy and Oncology</i> , 2020, 148, 181-188.	0.6	9
89	Time-Driven Activity-Based Costing Comparison of Stereotactic Radiosurgery to Multiple Brain Lesions Using Single-Isocenter Versus Multiple-Isocenter Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 999-1007.	0.8	9
90	Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease. <i>JAMA Network Open</i> , 2021, 4, e2034074.	5.9	9

#	ARTICLE	IF	CITATIONS
91	Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients. <i>Cancers</i> , 2021, 13, 1910.	3.7	9
92	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. <i>Radiotherapy and Oncology</i> , 2022, 166, 1-7.	0.6	9
93	A Fork in the Road: Choosing the Path of Relevance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 214-216.	0.8	8
94	Dosimetric feasibility of magnetic resonance imaging-guided tri-cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity. <i>Practical Radiation Oncology</i> , 2015, 5, 350-356.	2.1	8
95	Impact of Open Access to Physician Notes on Radiation Oncology Patients: Results from an Exploratory Survey. <i>Practical Radiation Oncology</i> , 2019, 9, 102-107.	2.1	8
96	Stereotactic Magnetic Resonance-guided Online Adaptive Radiotherapy for Oligometastatic Breast Cancer: A Case Report. <i>Cureus</i> , 2018, 10, e2368.	0.5	8
97	Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 207-209.	3.9	8
98	In Regard to Bauman et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1162-1163.	0.8	7
99	Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial. <i>British Journal of Radiology</i> , 2019, 92, 20181001.	2.2	7
100	Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. <i>Radiotherapy and Oncology</i> , 2022, 167, 226-232.	0.6	7
101	Dependence of Achievable Plan Quality on Treatment Technique and Planning Goal Refinement: A Head-and-Neck Intensity Modulated Radiation Therapy Application. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 817-824.	0.8	6
102	Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014). <i>Advances in Radiation Oncology</i> , 2019, 4, 738-747.	1.2	6
103	Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 404-411.	1.2	6
104	A Practical Guide for Navigating the Design, Build, and Clinical Integration of Electronic Patient-Reported Outcomes in the Radiation Oncology Department. <i>Practical Radiation Oncology</i> , 2021, 11, e376-e383.	2.1	6
105	Magnetic Resonance Imaging Guidance Mitigates the Effects of Intrafraction Prostate Motion During Stereotactic Body Radiotherapy for Prostate Cancer. <i>Cureus</i> , 2018, 10, e2442.	0.5	6
106	Magnetic Resonance-guided Inter-fraction Monitoring Opens Doors to Delivering Safer Reirradiation: An Illustrative Case Report and Discussion. <i>Cureus</i> , 2018, 10, e2479.	0.5	6
107	Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy. <i>British Journal of Radiology</i> , 2015, 88, 20150658.	2.2	5
108	Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e205-e218.	2.4	5

#	ARTICLE	IF	CITATIONS
109	Patient perspectives and treatment regret after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal cancer: Findings from a phase II trial. <i>Head and Neck</i> , 2019, 41, 2768-2776.	2.0	5
110	A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes. <i>Cancers</i> , 2022, 14, 939.	3.7	5
111	First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. <i>European Urology Oncology</i> , 2018, 1, 378-385.	5.4	4
112	The overthrow of the (evidence) hierarchy. <i>Practical Radiation Oncology</i> , 2011, 1, 81-82.	2.1	3
113	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. <i>Urology</i> , 2017, 107, 171-177.	1.0	3
114	If It Seems Too Good to Be True. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 305-307.	0.8	3
115	Comparison of Clinical Outcomes Stratified by Target Delineation for Patients Undergoing Stereotactic Body Radiotherapy for Spinal Metastases. <i>World Neurosurgery</i> , 2020, 136, e68-e74.	1.3	3
116	Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 786.	2.8	3
117	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	5.4	3
118	Provider-Level Variation in Treatment Planning of Radiation Oncology Procedures in the United States. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00441.	2.9	3
119	Weak Magnetic Fields Enhance the Efficacy of Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2021, 6, 100645.	1.2	3
120	Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel. <i>Frontiers in Oncology</i> , 2022, 12, 853246.	2.8	3
121	In Regard to Mariados et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 936-937.	0.8	2
122	Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>Eur Urol</i> 2017;71:766-73. <i>European Urology</i> , 2017, 72, e123-e124.	1.9	2
123	Training and Education Requirements for Authorized Users of Therapeutic Radiopharmaceuticals: Changes Under Consideration for 10CFR35.390 and Their Potential Impact. <i>Journal of the American College of Radiology</i> , 2019, 16, 1572-1576.	1.8	2
124	Potential Significant Changes in Nuclear Regulatory Commission Policies Regarding Training and Experience Requirements for the Use of Radiopharmaceuticals. <i>Journal of the American College of Radiology</i> , 2021, 18, 312-317.	1.8	2
125	Missing the Near Miss: Recognizing Valuable Learning Opportunities in Radiation Oncology. <i>Practical Radiation Oncology</i> , 2021, 11, e256-e262.	2.1	2
126	MRI-guided Dose-escalated Salvage Radiotherapy for Bulky Bladder Neck Recurrence of Prostate Cancer. <i>Cureus</i> , 2018, 10, e2360.	0.5	2

#	ARTICLE	IF	CITATIONS
127	Landscape of mortality during and within thirty days after non-palliative radiotherapy across eleven major cancer types. <i>Radiotherapy and Oncology</i> , 2022, 167, 308-316.	0.6	2
128	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 145-156.	2.5	1
129	Key considerations when reviewing subsequent primary cancers following radiotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e291.	10.7	1
130	Fast, Low-Dose Megavoltage-Topogram Localization on TomoTherapy: Initial Clinical Experience With Mesothelioma Patients. <i>Practical Radiation Oncology</i> , 2019, 9, 373-380.	2.1	1
131	Re: Aminsharifi et al., Major Complications and Adverse Events Related to the Injection of the SpaceOAR Hydrogel System Before Radiotherapy for Prostate Cancer: Review of the Manufacturer and User Facility Device Experience Database (From: Aminsharifi A, Kotamarti S, Silver D, et al., <i>J Endourol</i>) Tj ETQq1 1 0.784314 rgBT /Ov	2.1	1
132	Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 1334-1341.	1.2	1
133	The landscape of mortality during or within 30 days after non-palliative radiotherapy across 11 major cancer types.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6570-6570.	1.6	1
134	National variation in the delivery of radiation oncology procedures in the non-€facility€based setting. <i>Cancer Medicine</i> , 2021, 10, 4734-4742.	2.8	1
135	Psychological safety and near miss events in radiation oncology.. <i>Journal of Clinical Oncology</i> , 2019, 37, 231-231.	1.6	1
136	Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 327-327.	1.6	1
137	Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e94-e103.	1.9	1
138	Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison. <i>Advances in Radiation Oncology</i> , 2022, 7, 100944.	1.2	1
139	Correspondence. <i>Practical Radiation Oncology</i> , 2011, 1, 139.	2.1	0
140	Radiation therapy in the management of breast cancer brain metastases: the impact of receptor status on treatment response, intracranial recurrence, and survival. <i>Journal of Radiation Oncology</i> , 2016, 5, 401-409.	0.7	0
141	Technical Note: Dosimetric effects of couch position variability on treatment plan quality with an MRI-guided Co-60 radiation therapy machine. <i>Medical Physics</i> , 2016, 43, 4514-4519.	3.0	0
142	In Reply to Scott. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 217.	0.8	0
143	Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf?. <i>Cancer</i> , 2017, 123, 531-532.	4.1	0
144	Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 211-211.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer.. Journal of Clinical Oncology, 2020, 38, 208-208.	1.6	0
146	The intraprostatic immune balance after prostate SBRT in patients.. Journal of Clinical Oncology, 2020, 38, 339-339.	1.6	0
147	Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT. Applied Radiation Oncology, 2021, 10, 33-40.	0.5	0
148	The Model of an ASTRO Servant Leader. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1120-1121.	0.8	0
149	Evaluation of a centralized toxicity view in the electronic health record (EHR) for physician-recorded Common Terminology Criteria for Adverse Events (CTCAE).. Journal of Clinical Oncology, 2020, 38, 296-296.	1.6	0